AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03492580 — intervention group
Intervention type: DRUG
Intervention: Thiazolidinediones (TZD)
Description: No intervention or treatment assignment imposed by this study. Participants received TZD as a part of routine clinical practice. TZDs includes: pioglitazone, rosiglitazone, troglitazone.
Study NCT03492580 — intervention group
Intervention type: DRUG
Intervention: Sulfonylureas (SU)
Description: No intervention or treatment assignment imposed by this study. Participants received SU as a part of routine clinical practice. SUs includes: glipizide, glyburide, glimepiride, chlorpropamide, tolazamide, tolbutamide, acetohexamide
Study NCT03492580 — intervention group
Intervention type: DRUG
Intervention: Insulin
Description: No intervention or treatment assignment imposed by this study. Participants received Insulin as a part of routine clinical practice.
Study NCT02268019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tourniquet application
Study NCT02268019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinephrine injection
Study NCT01945554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical nerve root infiltration
Description: 4mg Mephamesone followed by 1ml of 0.5% bupivacaine (Bupivacain®) will be administered.
Study NCT01945554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar nerve root infiltration
Description: 40mg triamzinolone (Kenacort®) followed by 2ml of 0.5% bupivacaine (Bupivacain®) will be administered.
Study NCT01945554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mephamesone
Study NCT01945554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (Bupivacain®)
Study NCT01945554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kenacort®
Study NCT02433535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin is used to lower cholesterol, however, it also possess anti-inflammatory and immunomodulatory properties that may also alleviate allergic airway inflammation in asthma.
Study NCT02433535 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo pill will be given to the placebo group. There will be no detectible differences between study drug pill and placebo pill.
Study NCT03573115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene-Benzoyl Peroxide Gel 0.1-2.5%
Description: Topical gold microparticles (SEB-250) are delivered to two facial areas at baseline, patients are then prescribed a topical Adapalene-Benzoyl Peroxide Gel 0.1-2.5% for 6 weeks followed by a new exposure to gold microparticles (SEB-250)
Study NCT00357474 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial chemoembolization
Description: lipiodol, adriamycin and/or mitomycin
Study NCT00357474 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous ethanol injection therapy
Description: 99% ethanol 2-4cc per one session, two to three sessions per single procedure for one week
Study NCT04395131 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Clearum HF Hemodialyzer
Description: the hemodialyzer will be used 3x week for 3.5-4.5 hours with a Qb of at least 350 ml/min
Study NCT01438333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lactobacillus brevis tablets
Description: 5 tablets a day for 6 weeks
Study NCT01438333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: 5 tablets a day for 6 weeks
Study NCT02026882 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Supreme Laryngeal Mask Airway
Description: Supreme Laryngeal Mask Airway. Preoxygenation, rapid sequence induction and cricoid pressure. Induction of general anaesthesia.
Study NCT04157361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of breath condensate
Description: Breath condensate will be collected from the patients involved in study.
Study NCT04758559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myfood24
Description: An app to support monitoring of food and nutrient intake using robust validated methodology.
Study NCT02044510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Mirabegron 25mg PO daily for 2 weeks, with dose increase to Mirabegron 50mg PO daily for the remaining 8 weeks.
Study NCT02044510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo capsules to the intervention arm
Study NCT04368546 — intervention group
Intervention type: DRUG
Intervention: Sunitinib
Study NCT03362242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARO-AAT Injection
Description: Single or multiple doses of ARO-AAT by subcutaneous (sc) injections
Study NCT03626402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planning for the Care You Want
Description: 25-minute culturally specific educational video informing viewers about advance care planning options, palliative care, and hospice care and meeting with a lay health advisor to discuss content of the video.
Study NCT04309383 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ShuntCheck
Description: The intervention is an FDA-cleared device utilizing a transcutaneous thermal convection to analyze shunt flow.
Study NCT00077207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00077207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally
Study NCT00077207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00836225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 388626
Description: 4 arms of single dose s.c. injections: A 50 mg, B 100 mg, C 200 mg, D 400 mg, 2 arms of multi-dose: 3 s.c. injections over 1 week followed by 5 weekly s.c. injections: AA 50 mg, BB 100 mg 3 arms of multi-dose 13 weekly s.c. injections: AAA 50 mg, BBB 100 mg, CCC 200 mg, FFF 50 mg~Placebo: 0.9% sterile saline
Study NCT03362242 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: Calculated volume to match active comparator
Study NCT04167488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actigraphic measurement
Description: Physical activity assessed with actigraphic device worn during 7 days
Study NCT03016884 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zostavax vaccine
Description: After the screening, the eligible patients who provided the informed consent, will be administered the zoster vaccine.
Study NCT01920074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin Ointment 0.4%
Study NCT03841721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid oral tablet 300 mg/day for 5 day
Description: Linezolid oral tablet 300 mg/day for 5 day and blood sample were obtained by direct venipuncture at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hour after drug administration in day 5
Study NCT03569020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subsidy for food purchases and dietitian education
Description: $105/wk of DASH-like foods over 4 weeks purchased with the help of a dietitian in a proportion that reflects the DASH diet.
Study NCT03264066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Participants will receive cobimetinib 60 mg (3 tablets of 20 mg each) orally once a day on Days 1-21 of each 28-day cycle.
Study NCT03693131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icosapent (MND-2119)
Description: Icosapent (MND-2119) capsules.
Study NCT03693131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icosapent (EPADEL CAPSULES 300)
Description: Icosapent (EPADEL CAPSULES 300) capsules.
Study NCT03390023 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus Group
Description: Groups will last 60 to 90 minutes. Focus groups will be moderated by KUMC Juntos staff who are formally trained to conduct focus groups. General topics to be covered in focus groups include: attitudes, preferences and knowledge about prenatal care, clinical trial participation, and nutritional supplement use. Focus groups will be conducted in Spanish.
Study NCT01167140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryo-Touch II
Description: Percutaneous treatment with the device
Study NCT01412567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine+HBIG
Description: Recombinant hepatitis B vaccine at birth, 6 weeks, 10 weeks, and 14 weeks in the dose of 10 mcg (0.5 mL), by intramuscular injection in the anterolateral thigh; PLUS HBIG in the dose of 0.5 mL intramuscularly immediately after birth
Study NCT01412567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaccine+Placebo
Description: Recombinant hepatitis B vaccine at birth, 6 weeks, 10 weeks, and 14 weeks in the dose of 10 mcg (0.5 mL), by intramuscular injection in the anterolateral thigh; PLUS placebo intramuscularly immediately after birth
Study NCT04758559 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: usual care
Description: Patients will receive standard advice as provided by the clinical team, this may or may not include nutrition.
Study NCT01669863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECMO
Description: Use of veno-venous ECMO in non-intubated patients with ARDS
Study NCT03264066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
Study NCT01669863 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECMO in non-intubated patients
Description: Use of veno-venous ECMO in non-intubated patients with ARDS
Study NCT04299815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Sodium Lactate
Description: 25 grams of D/L lactate dissolved in 300mL water.
Study NCT04299815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous sodium lactate
Description: intravenous sodium lactate + oral sodium-chlorid solution
Study NCT00603473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin
Description: Orally administered gabapentin
Study NCT02691884 — intervention group
Intervention type: PROCEDURE
Intervention: maternal abdominal pressure
Description: The fetal cardiac response of either acceleration, deceleration or no change at all to the fetal heart- will be recorded and later on analyzed in reference to the amount of pressure applied from the 20th minute of CTG and for 5 minutes, using the FSR 400 sensor.
Study NCT04121949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADScor®System
Description: The CADScor®System is a low cost, low resource-demanding, non-invasive, radiation-free device using highly advanced analysis of sounds originating from blood flow turbulence in the coronary circulation and myocardial motion. Heart sound recordings are obtained transcutaneously during a 3 minutes recording period with a microphone mounted at the IC4. A CAD-score on a scale from 0 to 99 is estimated immediately after the recording with a fully automated algorithm. The algorithm measures eight acoustic properties and the resulting acoustic score is combined with the clinical risk factors gender, age, and hypertension. The entire procedure lasts approximately 10 minutes.
Study NCT03152474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Solumedrol 20mg
Description: Dosed Intravenous every 8 hrs.
Study NCT03152474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solumedrol 20mg
Description: Dosed Intravenous every 8 hrs.
Study NCT03152474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A 100,000 IU
Description: Dosed Intramuscular once daily
Study NCT03152474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A 100,000 IU
Description: Dosed Intramuscular once daily
Study NCT03152474 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo dosed intravenous every 8 hrs. or Intramuscular once daily.
Study NCT00975078 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adrenal insufficiency testing
Description: On the day getting the baseline data we will perform a low dose cosyntropin test to asses adrenal axis function.~All participants will then undergo an overnight 0.5mg dexamethasone suppression test. Thereby participants will take 0.5mg of dexamethasone at 11 pm and a fasting blood sample will be collected the next morning at 8 am to measure the serum cortisol level.~Six days later participants will start taking 0.5mg/kg body-weight prednisone each morning for 14 days.~On day 1, 3, 7 and 21 after withdrawal of prednisone the participant will undergo a low dose cosyntropin test. The investigators will take a blood sample before and 30 minutes after i.v. administration of 1ug of cosyntropin for the measurement of cortisol.
Study NCT00975078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 0.5mg/kg body-weight prednisone each morning for 14 days
Study NCT04689035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVLX-144
Description: Test drug
Study NCT04689035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT04367181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diffuse Correlation Spectroscopy (DCS)
Description: Diffuse correlation spectroscopy uses light in the near infrared spectral region to quantify non-invasively cerebral blood flow. The DCS device will be use to monitor blood flow changes over time in all ELGA enrolled babies
Study NCT04367181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amplitude Integrated Electroencephalography (aEEG)
Description: Amplitude Integrated Electroencephalography like EEG it is used clinically to monitor brain function in intensive care settings over longer periods of time. aEEG data will be correlated with CBF variation over time
Study NCT04533737 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Pre-filled syringe with 210 mg brodalumab in 1.5 ml solution for subcutaneous injection
Study NCT04533737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo solution is similar to the active guselkumab (Dummy 1) or brodalumab (Dummy 2) solution except that it does not contain any active substance
Study NCT04533737 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo solution is similar to the active guselkumab (Dummy 1) or brodalumab (Dummy 2) solution except that it does not contain any active substance
Study NCT06012877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Friendly Program
Description: The intervention, known as the Health-Friendly Programme, took place at the Clinical Skills and Simulation Centre of the Public University of Navarre. The intervention consisted of showing the children different scenarios that simulated various medical contexts, letting them experiment with the material and ask questions.~The structure and content of the intervention were intended to address two main issues. First, the health contexts with which school-age children may come into contact with; these are a consultation at a health centre and a hospital room. Second, the concerns, in relation to intrapersonal, procedural, environmental and interpersonal aspects, experienced by children when they interact with health care professionals or they are sick.~As reference material, the intervention is described in detail in the guide about the Health-Friendly Programme (Escalada-Hernández et al., 2021).
Study NCT04533737 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Guselkumab
Description: Pre-filled syringe with 100 mg guselkumab in 1 ml solution for subcutaneous injection
Study NCT02070289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865
Description: Tablets, 2.5 mg BID, 14 days
Study NCT02070289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets, BID, 14 days
Study NCT02070289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865
Description: Tablets, to be decided dose, BID or titration, 14 days
Study NCT02070289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets, BID or titration, 14 days
Study NCT02127892 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: unrelated BM with T cell depletion
Description: Remaining unmanipulated bone marrow will be processed to isolate CD34+ cells (T cell depleted).
Study NCT02127892 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: unrelated cord blood
Description: Cord blood will be thawed (and processed if ABO incompatibility) per institutional SOP.
Study NCT02127892 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: haplo BM with T cell depletion
Description: haplo-identical (parental) bone marrow will be processed for CD34+ cell isolation.
Study NCT02127892 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: unrelated PBSC with T cell depletion
Description: peripheral blood stem cell will be processed for CD34+ cell isolation.
Study NCT01356121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol will be initiated with a .5-1 mg/kg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
Study NCT01356121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
Study NCT02286297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGRATH® MAC
Description: video-laryngoscopy-1
Study NCT02286297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirTraq
Description: video-laryngoscopy-2
Study NCT02286297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope
Description: video-laryngoscopy-3
Study NCT00515970 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Curettage
Description: Curettage without subcutaneous tissue using a 7 mm ring curette and the fountain-pen technique (http://www.biopsypunch.com/kuerettagetechnik.htm; accessed on March 13, 2008). The curette is held between the thumb, index and middle finger. This method of holding enables precise guiding of the instrument, so that the piece of tissue can be removed in one well-targeted incision. After macroscopically complete removal, a safety margin is removed with the curette. It is used for histology to distinguish between R0 (excision margin without tumor cells) and R1 resection (excision margin containing tumor cells). Preparation with paraffin. Parallel, vertical sections for histologic diagnosis. Hematoxylin-eosin staining. Measurement of tumor thickness in mm.
Study NCT00515970 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep excision
Description: 12 o'clock mark. Excision with a scalpel down to the subcutaneous level. Plastic reconstruction. Three vertical, parallel bread loaf sections for histology. Preparation with paraffin. Staining with hematoxylin-eosin. Histologic diagnosis including report of tumor thickness in mm. Comment on complete removal (R0 versus R1). In case of R1 excision directed reoperations are performed until R0 is achieved.
Study NCT03264066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab Cohort 7
Description: Only for participants in cohort 7, the first dose of atezolizumab of 840 mg will be given by IV infusion on Day 15 of Cycle 1; thereafter, they will receive atezolizumab 840 mg IV infusion Q2W on Days 1 and 15 of Cycle 2 and all subsequent cycles.
Study NCT03166306 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PET-CT Imaging with [89Zr]-bevacizumab
Description: Subjects will receive 1 millicurie of 89Zr and less than 5 mg of bevacizumab, followed by PET-CT imaging.
Study NCT03166306 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET-CT Imaging with [89Zr]-bevacizumab
Description: Subjects will receive 1 millicurie of 89Zr and less than 5 mg of bevacizumab, followed by PET-CT imaging.
Study NCT02383537 — intervention group
Intervention type: OTHER
Intervention: Diabetes
Description: the trial is observational with no intervention
Study NCT03723928 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care disease monitoring
Description: Imaging and serum tumor markers are at the discretion of the treating physician (however imaging must be performed at least every 12 weeks).
Study NCT03723928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serum Tumor Marker directed disease monitoring
Description: Serum tumor markers every 4-8 weeks without imaging
Study NCT03723928 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03723928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03723928 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anxiety Questionnaire Administration
Description: Ancillary studies
Study NCT03723928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety Questionnaire Administration
Description: Ancillary studies